Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup

Mizuho healthcare specialist Jared Holz sees limited near-term catalysts amid likely congressional gridlock, favoring selective subsectors: he said pharma looked expensive relative to tech and pointed to medtech, including medical-device stocks near multi-year lows if regulation is reversed. The State Street Health Care Select ETF (XLV) rose 3% the day after Election Day, ended the week virtually flat, and is up around 32% since President Trump took office in January 2025—nearly 9 percentage points ahead of the S&P 500. Holz said a potential Democratic White House win in 2028 could support healthcare if Democrats also retain both chambers of Congress.

Analysis

The investable signal is dispersion, not a bullish healthcare call. A broad-sector rally that moves pharma and medtech together can leave the less policy-sensitive or better-supported businesses priced as if they share the same catalyst; it is not evidence that earnings expectations have improved. The reported outperformance of healthcare also raises the bar for fresh broad-sector buying, especially without valuation, positioning, or revisions data.

Near term (days to 1–3 months), congressional gridlock could limit major statutory change, but agencies, implementation choices, and court decisions can still affect reimbursement and device demand. Monitor earnings revisions and policy specifics rather than treating gridlock as a blanket sector hedge. Over 6–18 months, a durable device-sector rerating requires demonstrable easing of relevant regulatory or reimbursement constraints; a possible 2028 political shift is too contingent and distant to underwrite today.

Contrarian risk: pharma may not be the obvious funding source if its relative valuation premium is unsupported, but the article provides no valuation or earnings data to validate that claim. Conversely, medtech “multi-year lows” alone do not establish cheapness or upside. A policy rollback thesis fails if rules remain in force, implementation is delayed, or device-company guidance and order trends do not respond.

Key Decisions for Investors

• Avoid chasing XLV on political narrative alone; keep broad healthcare exposure neutral until earnings revisions or policy details confirm a fundamental catalyst. A further deterioration in sector earnings revisions would argue for reducing exposure rather than relying on the gridlock thesis.
• Set up a conditional, beta-adjusted long medtech / short pharma relative-value basket, not an outright sector bet. Initiate only after identifying the specific rules or reimbursement changes at issue and confirming improving medtech relative strength; size to limit losses if the policy catalyst stalls. Verify current valuations, exposure overlap, and constituent-level earnings trends before implementation.
• Treat a Democratic sweep or durable rollback of relevant rules as a 6–18 month upside catalyst, not a base-case near-term trade. Falsify the thesis if rules are retained or delayed, device guidance/order trends fail to improve, or medtech underperforms pharma after a concrete policy change.
• Before acting on the claim that pharma is unusually expensive, check comparable valuation measures, forward earnings revisions, and positioning. Without that evidence, avoid a standalone pharma short; a valuation premium by itself is not a timing signal.